港股異動 | 君實生物(1877.HK)漲超4% 與Anwita簽署許可協議 獲機構看好
格隆匯10月7日丨君實生物(1877.HK)現報50港元,漲4.71%,暫成交1674萬港元,最新總市值435億港元。君實生物曾於9月30日發公告稱,與Anwita簽署《許可協議》,Anwita授予公司在許可區域單獨使用協議中約定的Anti-HSA-IL-2Nα系列產品及相關的ANWITA技術和知識產權或與公司專有產品結合使用的獨佔許可。國泰君安認為,此次獲授權IL-2系列產品,使得君實生物成為國內該領域的領先者之一,有利於PD-1單抗市場下一階段的競爭。摩通曾指,君實生物繼續在臨牀、監管及業務發展上有穩健的進展,估計公司將繼續擴張海外市場足跡,重申增持評級,目標價68港元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.